Patents by Inventor Colin J. McKinlay

Colin J. McKinlay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240277870
    Abstract: There are provided herein, inter alia, complexes, compositions and methods for the delivery of therapeutic, diagnostic and imaging agents, including nucleic acid, into a cell. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.
    Type: Application
    Filed: March 12, 2024
    Publication date: August 22, 2024
    Inventors: Robert M Waymouth, Paul Wender, Jessica R. Vargas, Tim R. Blake, Colin J. McKinlay, Ronald Levy, Ole Audun Werner Haabeth, Nancy Benner, Katherine Near
  • Patent number: 10961263
    Abstract: Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: March 30, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Colin J. McKinlay, Paul A. Wender, Robert M. Waymouth
  • Publication number: 20200308200
    Abstract: Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.
    Type: Application
    Filed: April 9, 2020
    Publication date: October 1, 2020
    Inventors: Colin J. McKinlay, Paul A. Wender, Robert M. Waymouth
  • Patent number: 10654875
    Abstract: Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 19, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Colin J. McKinlay, Paul A. Wender, Robert M. Waymouth
  • Publication number: 20180319825
    Abstract: Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 8, 2018
    Inventors: Colin J. McKinlay, Paul A. Wender, Robert M. Waymouth